Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$1.12 - $1.57 $101,592 - $142,411
90,708 New
90,708 $134,000
Q3 2023

Nov 13, 2023

SELL
$1.07 - $1.39 $28,334 - $36,808
-26,481 Reduced 17.56%
124,331 $134,000
Q2 2023

Aug 14, 2023

SELL
$1.12 - $1.82 $361,260 - $587,048
-322,554 Reduced 68.14%
150,812 $194,000
Q1 2023

May 15, 2023

BUY
$1.25 - $2.0 $591,707 - $946,732
473,366 New
473,366 $624,000
Q3 2022

Nov 14, 2022

BUY
$1.1 - $12.2 $634,266 - $7.03 Million
576,606 New
576,606 $680,000
Q2 2022

Aug 15, 2022

SELL
$0.67 - $3.19 $75,043 - $357,295
-112,005 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$2.22 - $3.45 $20,399 - $31,702
9,189 Added 8.94%
112,005 $335,000
Q4 2021

Feb 01, 2022

SELL
$2.36 - $3.57 $20,373 - $30,819
-8,633 Reduced 7.75%
102,816 $272,000
Q3 2021

Nov 12, 2021

BUY
$3.5 - $4.5 $322,266 - $414,342
92,076 Added 475.28%
111,449 $405,000
Q2 2021

Aug 13, 2021

SELL
$3.09 - $4.54 $221,899 - $326,026
-71,812 Reduced 78.75%
19,373 $84,000
Q1 2021

May 14, 2021

BUY
$3.35 - $4.93 $166,652 - $245,252
49,747 Added 120.05%
91,185 $312,000
Q4 2020

Feb 16, 2021

BUY
$2.35 - $3.74 $97,379 - $154,978
41,438 New
41,438 $145,000

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.